术中光动力疗法在恶性胶质瘤综合治疗中的应用。

Intraoperative photodynamic therapy in complex treatment of malignant gliomas.

机构信息

Polenov Russian Neurosurgery Institute, St. Petersburg, Russia.

出版信息

Zh Vopr Neirokhir Im N N Burdenko. 2023;87(1):25-34. doi: 10.17116/neiro20238701125.

DOI:10.17116/neiro20238701125

PMID:36763550

Abstract

UNLABELLED

Treatment of malignant gliomas is an extremely difficult objective associated with difficult choice of correct strategy. Photodynamic therapy is still not the treatment standard in these patients although this approach significantly improves treatment outcomes in surgery of gliomas.

OBJECTIVE

To demonstrate the possibilities of chlorin e6-mediated photodynamic therapy for malignant glial tumors.

MATERIAL AND METHODS

There were 161 patients with malignant supratentorial glial tumors who were treated at the Polenov Russian Neurosurgery Institute between 2009 and 2016. Eighty patients comprised the main group (photodynamic therapy), 81 ones - control group (without photodynamic therapy).

RESULTS

Photodynamic therapy in complex treatment of malignant brain gliomas significantly increases overall survival in patients with Grade III gliomas up to 39.1±5.5 months (control group - 22.8±3.3 months) and Grade IV gliomas up to 20.7±4.7 months (control group - 13.5±2.3 months) (=0.0002). This method also increases relapse-free period in patients with Grade III gliomas up to 21.7±3.4 months (control group - 15.8±3.1 months) (=0.0002) and Grade IV gliomas up to 11.1±2.1 months (control group - 8.0±2.3 months) (=0.0001).

摘要

目的

展示氯乙酮介导的光动力疗法在恶性神经胶质瘤中的应用。

材料和方法

2009 年至 2016 年，在 Polenov 俄罗斯神经外科研究所治疗了 161 例幕上恶性神经胶质瘤患者。其中 80 例为观察组（光动力疗法），81 例为对照组（无光动力疗法）。

结果

恶性脑胶质瘤的综合治疗中，光动力疗法显著提高了 III 级胶质瘤患者的总生存率，达到 39.1±5.5 个月（对照组为 22.8±3.3 个月），IV 级胶质瘤患者的总生存率提高至 20.7±4.7 个月（对照组为 13.5±2.3 个月）（=0.0002）。该方法还延长了 III 级胶质瘤患者的无复发生存期，达到 21.7±3.4 个月（对照组为 15.8±3.1 个月）（=0.0002），IV 级胶质瘤患者的无复发生存期达到 11.1±2.1 个月（对照组为 8.0±2.3 个月）（=0.0001）。